Form 4: Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Granted Stock Options
SEC Form 4
Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, was granted stock options for 120,000 shares on December 12, 2024.
Summary
- Emil Kuriakose, the Chief Medical Officer of Terns Pharmaceuticals, was granted stock options for 120,000 shares of common stock.
- The options were granted on December 12, 2024, with an exercise price of $6.59 per share.
- The options vest over four years, with 25% vesting on the first anniversary of December 12, 2024, and the remaining 75% vesting monthly over the following three years.
- The options expire on December 11, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech and pharmaceutical industries.
- Vesting schedules of four years with a one-year cliff are also common, aligning with typical long-term incentive plans.
- The exercise price of $6.59 is not directly comparable without knowing the current market price of Terns Pharmaceuticals stock, but it is typical for options to be granted at or near the current market price.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 12/12/2024 | Date of stock option grant and start of vesting period. |
| 12/11/2034 | Expiration date of the stock options. |
| 12/16/2024 | Date the form was signed. |
Keywords
stock options, executive compensation, insider trading, Terns Pharmaceuticals, Emil Kuriakose, Chief Medical Officer, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.